#EMBER3
LightNews LightNews
erikahamilton9.bsky.social
#EMBER3

Imlunestrant (oral SERD) beats fulv (88% of SOC ET) in 2nd line ER+ #bcsm only in those with ESR1 mut

However, combo of Imlunestrant + abema wins in all-comers 5.5 vs. 9.5 mo regardless of ESR1

* note prior CDK not required

#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
December 11, 2024 at 3:27 PM
drsgraff.bsky.social
Ember3: Safety profile of imlunestrant looks good—minimal GI toxicity, no class toxicity concerns. The combo AEs are what we expect with abema. #SABCS24 @breastcancerdoc.bsky.social @oncoalert.bsky.social
December 11, 2024 at 3:37 PM
dfcibreastonc.bsky.social
Dr. Harold Burstein discussed the #EMBER3 study data in the #SABCS24 General Session 1.
December 11, 2024 at 3:54 PM
drsgraff.bsky.social
EMBER3 shows benefit of imlunestrant in patients with HR+ MBC and mESR1
and for the combination of imlunestrant and Abemaciclib for all patients, regardless of ESR1 status #SABCS24
@sabcs.bsky.social @breastcancerdoc.bsky.social @oncoalert.bsky.social
December 11, 2024 at 3:34 PM
stage4kelly.bsky.social
I think the biggest thing for ER+ MBC out of #SABCS24 is EMBER3 and imlunestrant, which showed benefit regardless of ESR1 status, but only statistically significant in people w/ mutant ESR1. #SABCS24
December 13, 2024 at 11:43 PM
drsgraff.bsky.social
EMBER3 Interesting subgroup breakdown shows the combo benefit persists independent of ESR1 status, prior CDK4/6 inhibition, and shows signal for CNS effect (very small numbers) #SABCS24 @breastcancerdoc.bsky.social @oncoalert.bsky.social @sabcs.bsky.social
December 11, 2024 at 3:36 PM
oncoalert.bsky.social
The OncoAlert🚨 #SABCS24 DAY2 Round Up
REGISTER AT www.OncoAlert360.com OR https://buff.ly/48Xpgz0

Discussing:
✅EMBER3 (Out on @NEJM )
✅Olympia
✅PRO B
✅ePROs
✅SHR-A1811
✅PHILA
✅Risk Reducing Surg in yBC patients w/BRCA mut
https://buff.ly/49xlNaA
Day One Video Round Up of The San Antonio Breast Cancer Symposium 2024
he OncoAlert🚨 #SABCS24 DAY2 Round Up REGISTER AT www.OncoAlert360.com OR https://buff.ly/48Xpgz0Discussing:✅EMBER3 (Out on @NEJM )✅Olympia✅PRO B✅ePROs✅SH...
youtu.be
December 12, 2024 at 4:15 PM
oncbrothers.bsky.social
< 2 weeks to #SABCS24, here is a📝 of🔑abstracts from #CommunityOncologists perspective.

- #EUROPA
- #EMBER3
- #SONIA
- #PADMA
- #TOUCH
- #DB012
- #OlympiA
- #KN522
- #REDUSE

#MedEd #bcsm #OncSky #breastcancer #MedSky @dr-rshatsky.bsky.social @drgattimays.bsky.social @hoperugo.bsky.social
November 26, 2024 at 4:10 PM
oncoalert.bsky.social
The OncoAlert🚨 hashtag#SABCS24 DAY2
Newsletter Out tomorrow 7am
REGISTER AT www.OncoAlert360.com OR buff.ly/48Xpgz0

Discussing
✅EMBER3 (Out on @NEJM )
✅Olympia
✅PRO B
✅SHR-A1811
✅PHILA
✅Risk Reducing Surg in yBC patients w/BRCA mut

@elisaagostinetto.bsky.social
@elisabettabonzano.bsky.social
December 12, 2024 at 1:18 AM
zoezhang.bsky.social
16/20 #TumorBoardTuesday @dr-rshatsky.bsky.social
🔙 to our case
EMBER3 would be a great option, but based on availability, pt got elacestrant
🚫 abema+fulvestrant:
-ESR1 Y537S 👉fulvestrant resistance.
-POSTMONARCH👉modest PFS benof abema+fulv vs placebo+fulv AND 🚫benefit in subgroup w/ prior ribo
January 15, 2025 at 1:45 AM
drsgraff.bsky.social
EMBER3 now in @NEJM highlights imlunestrant is better than fulvestrant in mESR1 MBC, and combo of abema+ imlumnestrant is better independent of mutations in all

Presentation soon @sabcs.bsky.social #SABCS24 Congrats @breastcancerdoc.bsky.social et al!

www.nejm.org/doi/full/10....
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer | NEJM
Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα (E...
www.nejm.org
December 11, 2024 at 2:46 PM
oncodaily.bsky.social
EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EMBER3 #ESMOBreast25 #BreastCancer #Imlunestrant #Abemaciclib
EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer - OncoDaily
ESMO Breast 2025: Imlunestrant + abemaciclib shows PFS benefit in CDK4/6i-pretreated ER+/HER2- advanced breast cancer, per EMBER-3 data.
oncodaily.com
May 15, 2025 at 10:34 PM
drgattimays.bsky.social
#EMBER3 results presented @sabcs.bsky.social #SABCS24 by @breastcancerdoc.bsky.social Main take aways: 1) Imlunestrant ⬆️ PFS > SOC in 1L, ESR1 mut, mER+ BC 2) Imlunestrant + abemaciclib ⬆️ PFS in 1L mER+ BC irrespective of ESR1 or PIK3CA mut 3) Imlunestrant ⬇️ CNS progression 4) OS immature #bcsm
December 11, 2024 at 3:43 PM
sanaalsukhun.bsky.social
Oral SERD #Imlunestrant in #EMBER3 is shifting the game! No need to check for ESR1 mutations when combined with #verzenio, as revealed by @breastcancerdoc.bsky.social at @sabcs.bsky.social Insightful discussion by @DrBurstein #BreastCancer #OncologyBreakthroughs

www.nejm.org/doi/full/10....
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer | NEJM
Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα (E...
www.nejm.org
December 12, 2024 at 4:22 PM
oncoalert.bsky.social
EMBER3 Presented at #SABCS24
Imlunestrant, a novel oral medication, significantly improved progression-free survival in patients with ER-positive, HER2-negative advanced breast cancer, especially those with ESR1 mutations.

Report with Peter Fasching
(high5 Onc)
https://buff.ly/3OZdxXF
December 18, 2024 at 2:37 PM
ascopost.bsky.social
🚨 New from #SABCS2024: Dr. Komal Jhaveri presents Phase III #EMBER3 trial results!

Imlunestrant, both as monotherapy & combo with Abemaciclib, shows improved PFS in ER+/HER2- advanced breast cancer.
#oncology #breastcancer #clinicaltrials ascopost.com/videos/2024-...
March 24, 2025 at 3:28 PM
stage4kelly.bsky.social
Another all oral option, based on BYLieve could be alpelisib + letrazole. What about off label use of Elacestrant + CDK4/6 inhibitor ?? This is being looked at in EMBER3 (imlunestrant) and ELEVATE (Elacestrant) #SABCS24
December 11, 2024 at 10:58 PM
schettinif87.bsky.social
My first takeaway from #SABCS24. The EMBER3 of new oral SERD imlunestrant vs fulvestrant or exemestane vs imlune+abemaciclib in HR+/HER2neg MBC. This study showed in II-line scenario that imlunestrant is superior to ET alone in ESR1mutant patients. AKA welcome to elacestrant 2 👇🏻
December 11, 2024 at 11:38 PM
drgattimays.bsky.social
#EMBER3 Continued … side effect profile with diarrhea, fatigue, nausea but most low grade. Also acknowledged was injection site pain/reaction from SOc - fulvestrant (commonly minimalists). Imlunestrant + abema therapy looks promising - may be another oral combination for patients with mBC
December 11, 2024 at 3:47 PM
longtail-news.bsky.social
Feed: "Oncodaily | Oncology News, Insights, Stories"
Published on Sunday, June 1, 2025
Gaia Griguolo: PROs from EMBER3 Trial Presented at ASCO25
Gaia Griguolo: PROs from EMBER3 Trial Presented at ASCO25 / ASCO25, cancer, EMBER3 Trial, Gaia Griguolo, Giuseppe Curigliano, OncoDaily, Oncology
oncodaily.com
June 1, 2025 at 10:40 AM
gerratana.bsky.social
#EMBER3 takeaways:

imlunestrant 🔼 PFS in patients with #ESR1 mut #MBC (5.5 vs. 3.8 mo)

Combination with abemaciclib further 🔼 PFS regardless of ESR1 and PIK3CA #ctDNA status (9.4 vs. 5.5 mo)

Previous CDK4/6i were mainly Palbo and Ribo in the MBC setting

#SABCS24 #bcsm #BreastCancer
December 11, 2024 at 4:13 PM